AUTOIMMUNE NEUROMUSCULAR JUNCTION DISORDER · GENERALISED AND OCULAR MG
A physician-led, laboratory-verified treatment programme targeting the autoimmune mechanisms behind neuromuscular junction dysfunction — designed to reduce antibody-mediated damage, restore immune tolerance and improve functional capacity in patients with generalised and ocular MG.
Request Medical ConsultationAbout the Condition
Myasthenia Gravis (MG) is a chronic autoimmune disorder in which antibodies attack components of the neuromuscular junction — the point where nerve signals are transmitted to muscles. The most common target is the acetylcholine receptor (AChR), though some patients produce antibodies against muscle-specific kinase (MuSK) or other postsynaptic proteins.
This antibody-mediated disruption impairs normal muscle contraction, leading to fluctuating weakness that worsens with activity and partially recovers with rest. Affected muscles typically include those controlling eye movement, eyelid position, facial expression, chewing, swallowing, speech and limb function. In severe cases, respiratory muscles may be compromised.
MG affects approximately 15–25 people per 100,000 worldwide. Current pharmacological management — pyridostigmine, corticosteroids, immunosuppressants, IVIG and plasma exchange — aims to control symptoms and suppress immune activity. Our cellular therapy programme works alongside these treatments, targeting the underlying immune dysregulation that drives the disease.
Generalised MG (AChR antibody-positive)
The most prevalent form, accounting for approximately 80–85% of generalised MG cases. Autoantibodies target acetylcholine receptors at the neuromuscular junction, causing complement-mediated damage and receptor loss. Weakness typically affects ocular, bulbar and limb muscles. Thymic abnormalities are common.
Ocular MG
Weakness confined to the extraocular muscles and eyelids. Presents with ptosis (drooping eyelids) and diplopia (double vision). Approximately 50–60% of ocular MG patients progress to generalised disease within two years. Early immunomodulatory intervention may reduce conversion risk.
MuSK-positive MG
Accounts for approximately 5–8% of generalised MG cases. Antibodies target muscle-specific kinase, a protein critical for neuromuscular junction maintenance. Often presents with prominent bulbar symptoms — difficulty swallowing, nasal speech, facial weakness. Responds poorly to acetylcholinesterase inhibitors. Requires distinct therapeutic strategy.
Seronegative MG
Patients with clinical features of MG but no detectable AChR or MuSK antibodies on standard assays. Represents approximately 5–10% of cases. Some harbour low-affinity antibodies detectable only with cell-based assays. Clinical course and treatment response vary widely.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, including antibody subtype, disease severity (QMG score), thymic status, current medication regimen and overall clinical profile.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2016 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
40
MG patients treated since 2013
78%
measurable functional stabilisation on QMG at 3–6 months
−3.4 pts
average QMG score change at 6 months — vs. expected +0.5 pts natural progression
70%
sustained functional stability with average 2 years of follow-up
78%
showed improvement in one or more measured domains
74%
retained independence in basic activities of daily living (ADL) at 12 months
Muscle strength (eyelid control, ptosis frequency, generalised weakness episodes, fatigability during sustained activity)
76%
Bulbar (swallowing function, aspiration risk, speech endurance)
66%
Respiratory (respiratory endurance, exacerbation frequency, immunosuppressant reduction)
70%
Quality of life (MG-ADL score, daily independence, sleep, fatigue)
74%
2–6 weeks
Initial functional response
2–5 months
Clinically meaningful change
1–2 years onward
Long-term stability — continuous monitoring
Important: Outcomes depend on MG subtype, antibody status, baseline QMG score, disease duration, thymic status and individual biological response.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationThe BioCells Program
Our MG programme combines five biological components into a single personalised protocol. Each protocol is constructed following detailed medical evaluation of the patient's antibody profile, disease severity, medication history and clinical priorities.
Minimally invasive administration
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
Relevant for MG patients, in whom certain anaesthetic agents carry risk of exacerbation or prolonged neuromuscular blockade.
No risk of immune rejection
MSCs are immunoprivileged: they express low levels of HLA-I, lack HLA-II and carry a minimal risk of rejection whether the protocol is autologous or allogeneic. Allogeneic MSC protocols do not require immunosuppression.
Targets the autoimmune mechanism, not just symptoms
Rather than only blocking acetylcholinesterase or broadly suppressing the immune system, our protocol targets the specific immune dysregulation — pathogenic antibody production, complement activation and regulatory T-cell deficiency — that drives MG.
Complements existing medication
Our programme is compatible with pyridostigmine, corticosteroids, azathioprine, mycophenolate, IVIG and other current standard medications. Patients do not need to discontinue existing treatment before commencing our protocol.
Patients from around the world
We work with patients from around the world. Airport transfers, accommodation, visa support and multilingual coordination are included in every treatment programme.
What It Is
T-regs are specialised immune cells that maintain immunological self-tolerance by suppressing autoreactive lymphocytes. In MG patients, T-reg function is typically impaired — contributing to the unchecked production of pathogenic autoantibodies.
How It Is Done
Delivered autologously (from the patient's own blood) or allogeneically (from a certified donor), based on the patient's immune status and clinical assessment. Preparation and quality testing performed in our Warsaw laboratory.
Biological Mechanisms
How This Helps in Myasthenia Gravis
Thymic abnormalities are present in a majority of AChR-positive MG patients, leading to defective immune regulation and persistent autoantibody production. T-regs directly address this regulatory deficit — suppressing the autoreactive immune cells that sustain the disease, reducing thymic-driven immune activation and working to restore the tolerance mechanisms that prevent the immune system from attacking the body's own neuromuscular junctions.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific antibody subtype, disease severity, thymic status, medication history and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current QMG status, antibody profile, medication history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation — including antibody testing, electromyography, thymic imaging and current immunosuppressive regimen. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Airport transfers, accommodation and visa support are included in the programme for international patients.
Structured rehabilitation sessions with our specialist, adapted to your current muscle function, fatigability pattern and daily activity requirements. Available at our clinic or remotely coordinated with your local medical team.
Your dedicated coordinator monitors functional status, tracks QMG and MG-ADL scores, provides clinical guidance and adjusts recommendations based on your recovery data. A medical-grade wearable bracelet supports continuous health tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of MG patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement. Importantly, our protocol is designed to avoid any agents that may trigger or worsen myasthenic exacerbation.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including signs of impending exacerbation or respiratory compromise — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active myasthenic crisis requiring mechanical ventilation
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rehabilitation specialist
monitors muscle function, fatigability and overall clinical status
Personalised rehabilitation programme
adapted to current functional capacity and MG severity
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, medication adjustment guidance and response to any changes in status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Immunological remodelling is a gradual process. The period following treatment is as medically important as the treatment itself — consistent monitoring, rehabilitation and coordination with your existing medical team are essential for sustained benefit.
Patient Stories
“Four years on prednisone. The side effects were becoming their own problem: weight, bones, mood. After the programme in Warsaw, my neurologist in Rome managed to halve the dose over the following months. The daily fatigue lifted enough that I started driving again.”
Patient
Generalised MG (AChR-positive) · Italy
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationPatient Cases
Documented treatment outcomes recorded by the BioCells Medical team after personalised regenerative medicine protocols.
Get Started
If you or someone you love has been diagnosed with Myasthenia Gravis, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, antibody profile, current treatment regimen and individual clinical situation.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
